TPP Trade Deal Sealed: Did Brand-Name Biopharma Really Lose?
This article was originally published in SRA
After more than six years of intense efforts to lobby a group of Asia-Pacific trade ministers - a pact that eventually involved representatives from 12 nations - the innovator biopharmaceutical industry failed to get what it most wanted in the Trans-Pacific Partnership (TPP): 12 years of data exclusivity protection for biologics against biosimilars1,2.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.